DE:3G6 Stock Latest News
Company AnnouncementsGNI Group to Join TOPIX as Global Biopharma Footprint Expands3w ago
Company AnnouncementsGNI Group Wins FDA Approval for First Proprietary Medtech Wound Matrix1M ago
Company AnnouncementsGNI Group Announces Change in Major Shareholder Following Blackstone-Linked Stake Sale2M ago
Company AnnouncementsGNI Group Maps Out ‘Second Founding Phase’ in Q2 FY2026 Results2M ago
Company AnnouncementsGNI Group Lifts 2026 Revenue Outlook After AYUMI Deal, Holds Back Profit Guidance2M ago
Company AnnouncementsGNI Group Narrows Losses in Q2 but Limits FY2026 Guidance to Revenue Amid Drug Investment Uncertainty2M ago
Company AnnouncementsGNI Group Makes AYUMI a Wholly Owned Unit and Raises ¥26.8 Billion via Share Issuance4M ago
Company AnnouncementsGNI Sets July 1 Payment Date for Share Issue Funding AYUMI Acquisition4M ago
Company AnnouncementsGNI Group Secures ¥20 Billion Covenant-Linked Loan for Ayumi Acquisition4M ago
Company AnnouncementsGNI’s Gyre Therapeutics files Form S-3 tied to Cullgen acquisition4M ago
Company AnnouncementsGNI Group Announces Transformational Acquisition of Ayumi Pharmaceutical Holdings4M ago
Company AnnouncementsGNI Group to Buy AYUMI Pharmaceutical Holdings and Issue New Shares to Bolster Japan Platform4M ago- Company AnnouncementsGNI Group Widens Q1 Loss as Drug Investment and Reorganization Weigh on Earnings5M ago
- Pre-Earnings3G6 Earnings Report this Week: Is It a Buy, Ahead of Earnings?5M ago
- Company AnnouncementsGNI Group’s F351 Liver Fibrosis Drug Wins NDA Acceptance and Priority Review in China5M ago
- Company AnnouncementsGyre Ramps Up F351 and Cullgen Investments as Q1 Swings to Loss5M ago
Company AnnouncementsGNI Group Reshapes Top Management as Gyre Advances Cullgen Acquisition5M agoCompany AnnouncementsGNI Group Starts Phase 2/3 Trial of Pirfenidone for Cancer-Related Lung Injury in China6M ago